BioSpace News Archive

NS Pharma is pleased to announce that previously reported long-term efficacy and safety data (final visit up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) have been published in the May issue of the Journal of Neuromuscular Diseases.

National Surgical Centers Stockton (NSC Stockton), an outpatient surgery center, is now offering high-frequency spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN).

Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.

Hubly Surgical announced today that they received 510k clearance from the FDA to market the Hubly Drill, an innovative medical technology developed with the goal of making burr hole procedures safer and more efficient in any setting, including outside of the operating room.

Turn Biotechnologies announced that Chief Executive Officer, Anja Krammer, will present an updated corporate overview at the JMP Securities Life Sciences Conference in New York City being held May 15th-16th, 2023 in New York City.

Anthos Therapeutics presented details of the development of a novel patient-reported outcome assessment scale to measure the patient relevant burden of oral anticoagulant treatment at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.

Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).

Oxford Biomedica Solutions LLC, offers The Full Solution™ services, which includes end-to-end development and manufacturing capabilities.

Emboline, Inc. today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial (NCT05684146) at New York-Presbyterian Hospital/Columbia University Medical Center in New York, NY.